Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis

Clin Nephrol. 1993 Sep;40(3):155-9.

Abstract

A retrospective study compared two groups with type IV lupus nephritis with very similar activity and chronicity indices on renal biopsy. One group was treated with intermittent pulse cyclophosphamide (IPC), and the other was not. The IPC group demonstrated a greater decrease in serum creatinine at 6 months, 12 months and most recent follow-up intervals (p < 0.01, p < 0.05, p < 0.001). Reduction in proteinuria was similar in the two groups. Two of eight in the no-IPC group progressed to ESRD while only one of twelve in the IPC group developed ESRD. The findings suggest that IPC preserves renal function in Type IV nephritis. Furthermore it is suggested that a lower cumulative dosage than previously reported may reduce toxicity without a significant loss of efficacy.

Publication types

  • Comparative Study

MeSH terms

  • Creatinine / blood
  • Cyclophosphamide / administration & dosage*
  • Cyclophosphamide / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / epidemiology
  • Kidney Function Tests
  • Lupus Nephritis / diagnosis
  • Lupus Nephritis / drug therapy*
  • Lupus Nephritis / epidemiology
  • Male
  • Retrospective Studies
  • Time Factors

Substances

  • Cyclophosphamide
  • Creatinine